THE UNIVERSITY OF HONG KONG HKU EYE CENTRE INAUGURAL REPORT
Dean’s Foreword 院長序言 Chairperson’s Foreword 系主任引言 I. Research at HKU Ophthalmology 香港大學眼科學系⸺研究成果 II. Technologies and Innovations at HKU Eye Centre 香港大學眼科中心⸺技術與創新 III. Community and Charity Clinical Services 社區及慈善臨床服務 IV.Ophthalmology Training and Education 眼科專科培訓和教育 V. Our Team 我們的團隊 Contents 目錄 2 4 6 20 30 38 48
Dean’s Foreword 2
The Faculty has been ramping up its capacity in recent years to ensure our graduates can serve the needs of the Hong Kong population, and to widen our research agenda. The new HKU Eye Centre exemplifies our success in these pursuits. Hong Kong urgently needs more doctors trained in treating conditions of the eye. The city already has a disreputably long waiting period for cataract operations, averaging four years, and this will be exacerbated as the population continues to age. HKUMed’s e�orts to provide focused training and research in this field has, until now, been limited by the fact that our Department of Ophthalmology has been spread across several locations, which has led to a duplication of manpower and equipment, lower e�ciency and limited capacity to expand. In one fell swoop, the HKU Eye Centre is a game-changer. Sta�ng, equipment and expertise are now centralised, which not only improves e�ciency but also generates synergies. It also makes it far easier to provide our students with access to state-of-the-art teaching innovations, such as tele-ophthalmic care, high-fidelity ophthalmoscope simulation and surgical teaching using 3D displays. This will ensure graduates have more exposure and insights to conditions of the eye. The Centre will also serve as a regional hub for advancing research and innovation in clinical ophthalmology and vision sciences, building on the high academic standards that run across the Faculty. HKUMed was named one of the world’s top 20 medical schools in the 2022 Times Higher Education (THE) ‘clinical and health’ rankings. HKU Eye Centre is a welcome and much-needed addition to our clinical capacity. Such a milestone achievement not only provides an essential service to the community, but lays the groundwork for future impact in Hong Kong and the region. Gabriel Leung Dean of Medicine 港大醫學院近年不斷提升實力，確保畢業生能夠 滿足香港人對醫療服務的需求，並擴充研究範疇。 新成立的香港大學眼科中心正是達成這些目標的 佼佼者。 香港迫切需要更多接受過眼科治療培訓的醫生。 眾所周知，本港的白內障手術等候時間很長，平 均長達四年，並將隨著人口持續老化而進一步加 劇。迄今為止，港大醫學院在提供眼科重點培訓 和研究的努力一直受到各種限制：我們的眼科學 系分布在多個地點，導致人手及設備重疊、效率 降低，亦難於擴充。 香港大學眼科中心的成立，瞬間就改變了局面。 此後，人手、設備和專業知識都得以集中，不僅 可提高效率，更可產生協同效應。同時，我們的 學生更容易受惠於最先進的教學創新，例如遠程 眼科護理、高擬真度檢眼鏡模擬及3D顯示器手術 教學等，以加強畢業生對眼睛狀況的認識和了解。 此外，香港大學眼科中心將會成為推動臨床眼科 及視覺科學研究與創新的地區樞紐，在港大醫學 院高學術水平的基礎上持續邁進。港大醫學院在 2022年泰晤士高等教育的「臨床與健康」排名中 獲評為世界排名首20位的醫學院之一。 香港大學眼科中心及時滿足了我們提升臨床實力 的需求，是一項令人欣喜的里程碑，不僅為社區 提供不可或缺的服務，更為日後在本港及亞太地 區作貢獻奠定基礎。 梁卓偉教授 醫學院院長 3 HKU Eye Center Inaugural Report The University of Hong Kong 院長序言
Chairperson’s Foreword 4
The HKU Eye Centre is a state-of-the-art ophthalmic centre established by the Department of Ophthalmology at The University of Hong Kong with the support of the Faculty of Medicine and our donors. The Centre’s mission is to conduct cu�ing edge clinical and translational research in ophthalmology, to deliver professional and patient-centered ophthalmic care, and to provide high quality clinical training to HKU medical students and postgraduate students. Strategically located in the heart of the Southern District of Hong Kong (7/F, Marina 8, Heung Yip Road, Wong Chuk Hang), the Centre centralizes the latest ophthalmic technologies and expertise of our Department to create synergies. The Centre is operated by a team of dedicated professoriate ophthalmologists, ophthalmic nurses, optometrists, orthoptists, ophthalmic imaging technicians, and houses three fully-equipped consultation rooms, an advanced ophthalmic investigation suite, and two day-procedure operating theatres. The increasing waiting time for ophthalmology outpatient consultation appointments and cataract surgeries at public hospitals has undermined prompt delivery of clinical services to many visually impaired patients in Hong Kong. The HKU Eye Centre is commi�ed to assist the socially disadvantaged and underprivileged community so patients who could not otherwise a�ord expensive eye care services would also be able to receive high quality ophthalmology consultation and surgery. The Department is thankful to our donors for their generous support to its charity community programs and research projects. The Department anticipates the HKU Eye Centre to become a regional hub for transformative clinical and translational research, multidisciplinary innovations in medical education, and high-quality ophthalmic care, serving people in Hong Kong, the Greater Bay Area of China and beyond. Christopher Leung Director of HKU Eye Centre Department Chairperson and Clinical Professor 「香港大學眼科中心」是由香港大學眼科學系在醫 學院和捐助者的支持下成立的先進眼科中心。中 心的使命是為我們的眼科患者提供專業，全面， 和以患者為本的治療和護理；在眼科和視覺科學 方面進行臨床科研和轉化科研；並為香港大學醫 科學生和研究生提供優質的臨床培訓。中心戰略 性地座落於香港南區的心臟地段（黃竹坑香葉道8 號，7樓），凝聚了香港大學眼科學系教職員的專 業技能和多項設備，以達到協同作用。中心由敬 業的眼科教授、眼科護士、視光師、視覺矯正師 和眼科成像技術人員組成的團隊營運， 並設有三 個設備齊全的診症室，一所先進的檢查室，和兩 個日間手術室。 香港公立醫院眼科門診預約及白內障手術的輪候 時間不斷延長，使不少視障患者得不到迅速的診 治或手術治療。香港大學眼科中心將致力協助弱 勢社群，讓缺乏經濟能力的視障患者也可以得到 高質素的眼科診治及手術治療。香港大學眼科學 系感謝捐助者對社區慈善計劃和本學科研究項目 推動的慷慨支持。 本學系祈盼香港大學眼科中心成為區域性樞紐， 為香港，中國大灣區，甚至境外地區提供高質量 的眼科醫療服務， 推動最先進的臨床和轉化研 究，和提升創新醫學教育。 梁啟信教授 香港大學眼科中心總監 眼科學系系主任及臨床教授 5 HKU Eye Center Inaugural Report The University of Hong Kong 系主任引言
I. Research at HKU Ophthalmology 6
香港大學眼科學系研究成果 ⸺ 7
During 2021-2022, HKU Ophthalmology professoriate sta� have secured HK$20,466,124.68 research grant from the University Grants Commi�ee Research Grants Council General Research Fund, Food and Health Bureau Health and Medical Research Fund, and the medical device companies and pharmaceutical industry as principal investigators, published 84 research papers in major peer-reviewed academic journals including Nature Biomedical Engineering (Impact Factor: 25.7), Ophthalmology (Impact Factor: 12.1), and Cell Death & Disease (Impact Factor: 8.5), and received multiple international research awards including the Asia Pacific Academy of Ophthalmology Senior Achievement Award 2021, Hong Kong Most Outstanding Leaders Awards 2021, and the Japanese Ophthalmological Society International Young Investigator Award 2021 among others. 香港大學眼科學系教職員工於2021-2022年間， 成功申請多個研究基金，當中包括大學教育資助 委員會研究資助局優配研究金、食物及衛生局醫 療衛生研究基金，和醫療設備及製藥公司配置的 研究基金，發表了共84篇研究論文，包括在期刊 Nature Biomedical Engineering （影響因子: 25.7）、 Ophthalmology （影響因子: 12.1）和Cell Death & Disease （影響因子: 8.5），及榮獲多項國際性研究 獎項，包括2021年亞太眼科學會高級成就獎、 2021年香港傑出領袖獎和2021年日本眼科學會國 際青年研究員獎。 1. Research Outputs 2021-2022 2021-2022 年研究成果 Ophthalmology 2022 Nature Biomedical Engineering 2022 Cell Death & Disease 2022 8 Research at HKU Ophthalmology 香港大學眼科學系——研究成果
A. List of external research funding Awarded as Principal Investigator in 2021-2022 2021-2022 年授予首席研究員的校外研究資助項目名單 Total HK$ 20,466,124.68 Research Grants Council Gernal Research Fund (2020/21) – Metformin as a neuroprotective therapy for glaucoma – A randomized controlled trial [Principal Investigator - Professor Christopher Leung] Health and Medical Research Fund (2020/21) – Applying virtual reality simulations to determine the development of vision – related disability in patients with glaucoma – A 3-year prospective study [Principal Investigator - Professor Christopher Leung] Arctic Vision Research Grant (2021) – Development of a microRNA–based ocular gene therapy for neuroprotection in glaucoma [Principal Investigator - Professor Christopher Leung] Glaucoma/Myopia OCT Phenotyping Consortium (GMPOC) (2021/22) – A multicenter study of myopic and/or glaucomatous optic nerve head, retinal nerve fiber layer and macula parameters measured with optical coherence tomography (OCT) [Hong Kong Principal Investigator - Professor Christopher Leung] Topcon Research Foundation (2021/22) – Application of wide-field optical coherence tomography imaging and trend-based progression analysis for detection of glaucoma of progression [Principal Investigator - Professor Christopher Leung] Health and Medical Research Fund (2020/21) – Preclinical evaluation of extra virgin olive oil and lutein-in-extra-virgin-olive-oil supplementation as a new avenue for prevention of retinopathy of prematurity [Principal Investigator - Dr Amy Lo] Health and Medical Research Fund (2020/21) – Randomized control trial on the efficacy of a smartphone application (Glaucomapp) on monitoring and promoting disease awareness and medication adherence on Chinese glaucoma patients [Principal Investigator - Dr Bonnie Choy] Alcon (2021) – CLOVE study: Clareon Intraocular lens stability in Vitrectomy patients [Principal Investigator - Dr Nicholas Fung] Roche Hong Kong Limited (2021) – Avonelle X: multicenter, Open-Label Extension Study to evaluate the long-term safety and tolerability of faricimab in patients with neovascular age-related macular degeneration [Principal Investigator - Dr Nicholas Fung] Roche Hong Kong Limited (2021) – Rhone X: A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients with Diabetic Macular Edema [Principal Investor - Dr Nicholas Fung] Roche Hong Kong Limited (2021) – Balaton- A Phase III, Multicenter Randomized, Double-masked, active comparator controlled study to evaluate the efficacy and safety of Faricimab in patients with macular edema secondary to branch retinal vein occlusion [Principal Investigator - Dr Nicholas Fung] Roche Hong Kong Limited (2021) – Comino-A Phase III, Multicenter Randomized, Double-masked, active comparator controlled study to evaluate the efficacy and safety of Faricimab in patients with macular edema secondary to central retinal of hemiretinal vein occlusion [Principal Investigator - Dr Nicholas Fung] Amgen Hong Kong (2021) – A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects with Neovascular Age-related Macular Degeneration [Principal Investigator - Dr Nicholas Fung] 9 HKU Eye Center Inaugural Report The University of Hong Kong
Roche Hong Kong Limited (2022) – Salween MR43808: A Phase IIIb/IV, Multicenter, Open-Label, Single-Arm Study to Investigate the E�cacy and Safety of Faricimab (Ro6867461) in Patients with Polypoidal Choroidal Vasculopathy [Principal Investigator - Dr Nicholas Fung] Roche Hong Kong Limited (2022) – MR42410: A Phase IIIb, Multicenter, Randomized, Visual Assessor-Masked Study of the E�ectiveness And Safety of A 36-Week Refill Regimen for the Port Delivery System with Ranibizumab vs Aflibercept Treat & Extend in Subjects with Neovascular Age-Related Macular Degeneration (DIAGRID) [Principal Investigator - Dr Nicholas Fung] ONL Therapeutics (2022) – ONL1204-GA-001: A Phase 1b Multicenter, Randomized, Controlled, Multi-dose Study of the Safety and Tolerability of ONL1204 Ophthalmic Solution in Patients with Geographic Atrophy (GA) Associated with Agerelated Macular Degeneration (AMD) [Principal Investigator - Dr Nicholas Fung] Ripple Therapeutics (2022) – IBE-814-IVT-1: Evaluation of Safety and E�cacy of the IBE-814 Intravitreal Implant in Patients with Diabetic Macular Oedema and Macular Oedema due to Retinal Vein Occlusion [Principal Investigator - Dr Nicholas Fung] Alcon (2021) – 20K study: comparing the e�ciency and safety of 10K and 20K high speed vitrectomy cu�er [Principal Investigator - Dr Nicholas Fung] Health and Medical Research Fund (2021/22) – Deep Learning Colour Fundus Image Analysis for Triage of Chinese Elderly Patients Presenting with Chronic Vision Loss [Principal Investigator - Dr Kendrick Shih] Health and Medical Research Fund (2021/22) – Developing AI-powered retinal layer segmentation to improve the detection of glaucoma & its progression from wide-field OCT imaging [Principal Investigator - Dr Alexander Lam] 10 Research at HKU Ophthalmology 香港大學眼科學系——研究成果
B. Representative Research Publications 2021-2022 38 First or Corresponding Authored Publications in 2021-2022 *Corresponding Author (1) Zhang X, Guo PY, Lin C, Li F, Nguyen A, Sakata R, Higashita R, Okamoto K, Yu M, Kato C, Aihara M, Aung T, Lin S, *Leung CKS. Assessment of Iris Trabecular Contact in Eyes with Gonioscopic Angle Closure. Ophthalmology. 2022 (In Revision).ﾠ (2) *Leung CKS, Guo PY, Lam AKN. Retinal Nerve Fiber Layer Optical Texture Analysis (ROTA): Involvement of the Papillomacular Bundle and Papillofoveal Bundle in Early Glaucoma. Ophthalmology. 2022 (In Press) (3) *Leung CKS, Lam AKN, Weinreb RN, Garway-Heath DF, Yu M, Chiu V, Wan K, Wong M, Wu K, Cheung CY, Lin C, Chan C, Chan NC, Kam KW, Lai G. Retinal nerve fiber layer Optical Texture Analysis (ROTA) – A new paradigm for diagnostic evaluation of optic neuropathy. Nature Biomedical Engineering. 2022;6:593-604. (4) *Leung CKS, Ren ST, Chan PPM, Wan KHN, Kam AKW, Lai GWK, Chiu VSM, Ko MWL, Yiu CKF, Yu MCY. Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial. Trials. 2022;23:45. (5) Wong MOM, Lai IS, Chan PP, Chan NC, Chan AY, Lai GW, Chiu VS, *Leung CKS. E�cacy and safety of selective laser trabeculoplasty and pa�ern scanning laser trabeculoplasty: A randomised clinical trial. Br J Ophthalmol. 2021;105:514-520. (6) Mak HK, *Leung CKS. MicroRNA-based therapeutics for optic neuropathy: opportunities and challenges. Neural Regen Res. 2021;16:1996-1997 (Invited Editorial). (7) Goit RK, Taylor AW, *Lo ACY. Anti-inflammatory α-Melanocyte-Stimulating Hormone Protects Retina A�er Ischemia/ Reperfusion Injury in Type I Diabetes. Front Neurosci. 2022 Feb 25;16:799739. (8) Goit RK, Taylor AW, *Lo ACY. The central melanocortin system as a treatment target for obesity and diabetes: A brief overview. Eur J Pharmacol. 2022 Jun 5;924:174956. (9) Hu T, *Lo ACY. Collagen-Alginate Composite Hydrogel: Application in Tissue Engineering and Biomedical Sciences. Polymers (Basel). 2021 Jun 2;13(11):1852. (10) Tang LHC, Fung FKC, Lai AKW, Wong IYH, Shih KC, *Lo ACY. Autophagic Upregulation Is Cytoprotective in Ischemia/ Reperfusion-Injured Retina and Retinal Progenitor Cells. Int J Mol Sci. 2021 Aug 6;22(16):8446. (11) Tsang JKW, Wolf SA, Pompoes IM, Joussen AM, Lam WC, Yang D, *Lo ACY. Potential E�ects of Nutraceuticals in Retinopathy of Prematurity. Life (Basel). 2021 Jan 22;11(2):79. (12) Yang M, So KF, Lam WC, *Lo ACY. Cell Ferroptosis: New Mechanism and New Hope for Retinitis Pigmentosa. Cells. 2021 Aug 21;10(8):2153. (13) Zhou T, Lee A, *Lo ACY, Kwok JSWJ. Diabetic Corneal Neuropathy: Pathogenic Mechanisms and Therapeutic Strategies. Front Pharmacol. 2022 Feb 23;13:816062. (14) Yang M, Tsui MG, Tsang JKW, Goit RK, Yao KM, So KF, Lam WC, *Lo ACY. Involvement of FSP1-CoQ10-NADH and GSHGPx-4 pathways in retinal pigment epithelium ferroptosis. Cell Death Dis. 2022 May 18;13(5):468. (15) *Lo ACY, Yang M. Lycium barbarum polysaccharides and ferroptosis: jumping into the era of novel regulated cell death. Neural Regen Res. 2022 Jul;17(7):1473-1474. 11 HKU Eye Center Inaugural Report The University of Hong Kong
(16) Chow SC, Lam PY, *Choy BNK. Patient-centred care in ophthalmology: current practices, e�ectiveness and challenges. Graefes Arch Clin Exp Ophthalmol. 2022 Apr 21. (17) *Choy BNK, Pang JCS, Zhu MM, Ng ALK, Chan JCH, Fan MCY, Iu LPL, Chiu PKC, Kwan JSK, Lai JSM. Association between functional status and ocular surface disease among local elderly population in Hong Kong. Semin Ophthalmol. 2021 Oct 3;36(7):497-500. (18) Lam PY, Chow SC, Lai JSM, *Choy BNK. A review on the use of telemedicine in glaucoma and possible roles in COVID-19 outbreak. Surv Ophthalmol. 2021 Nov-Dec;66(6):999-1008. (19) Zhu M, Choy NKB, You QS, Chan JCH, Ng LKA, Shih KC, Cheung JJC, Wong KWJ, Shum JWH, Ni MY, Lai JSM, Leung GM, Wong YHI. Optic disc and peripapillary vessel density measured with optical coherence tomography angiography and its associations in Chinese adults: a large population-based study. British Journal of Ophthalmology. 2021, bjophthalmol-2020-318199. (20) Li YYS, Vardhanabhuti V, Tsougenis E, Lam WC, *Shih KC. A Proposed Framework for Machine Learning-Aided Triage in Public Specialty Ophthalmology Clinics in Hong Kong. Ophthalmol Ther. 2021 Dec;10(4):703-713. (21) Rhee J, *Shih KC. Use of Gene Therapy in Retinal Ganglion Cell Neuroprotection: Current Concepts and Future Directions. Biomolecules. 2021 Apr 15;11(4):581. (22) Wong HL, Bu Y, *Chan YK, *Shih KC, Lycium barbarum polysaccharide promotes corneal Re-epithelialization a�er alkaline injury. Experimental Eye Research. 2022, 109151. (23) Bu Y, Chan YK, Wong HL, Poon SHL, Lo ACY, *Shih KC, Tong L. A Review of the Impact of Alterations in Gut Microbiome on the Immunopathogenesis of Ocular Diseases. Journal of Clinical Medicine. 2021. (24) Wong KWJ, Zhu M, Lam CHJ, Leung MK, Lian JX, Lam CLK, *Shih KC, Lai JSM, Prospective Comparative Study Investigating Agreement between Tele-Ophthalmology and Face-to-face Consultations in Patients Presenting with Chronic Visual Loss. Ophthalmology and Therapy. 2022, Apr 13. (25) Poon SHL, Cheung JJ, *Shih KC, Chan YK. A systematic review of multimodal clinical biomarkers in the management of thyroid eye disease. Rev Endocr Metab Disord. 2022 Jun;23(3):541-567. (26) Chow SC, *Chan JC. Review on the Use of Topical Ocular Hypertonic Saline in Corneal Edema. Cornea. 2021 Apr;40(4): 533-539. (27) Jia S, Chen F, Wang H, Kesavamoorthy G, Lai JS, Wong IY, Chiu K, *Chan JC. E�ect of Vitamin D3 on Regulating Human Tenon's Fibroblasts Activity. Transl Vis Sci Technol. 2021 Jul 1;10(8):7. (28) Lian JX, McGhee SM, So C, Kwong ASK, Sum R, Tsui WWS, Chao DVK, *Chan JCH. Screening for diabetic retinopathy with di�erent levels of financial incentive in a randomized controlled trial. J Diabetes Investig. 2021 Sep;12(9):1632-1641. (29) Wong JKW, Leung TK, Lai JS, *Chan JC. Evaluation of Adverse E�ects of Topical Glaucoma Medications on Trabeculectomy Outcomes Using the Glaucoma Medications Intensity Index. Ophthalmol Ther. 2022 Feb;11(1):387-401. (30) *Chan JC, Cheung RK, Wong PW, Lai JS. Peripheral anterior synechiae a�er selective laser trabeculoplasty among Chinese patients. Graefes Arch Clin Exp Ophthalmol. 2022 May 7. 12 Research at HKU Ophthalmology 香港大學眼科學系——研究成果
(31) Chow SC, Lam PY, Lam WC, *Fung NSK. The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity - a current review. Eye. 2022. (32) ) Lam PY, Chow SC, Lam WC, Chow LLW, *Fung NSK. Management of Patients with Newly Diagnosed Diabetic Mellitus: Ophthalmologic Outcomes in Intensive versus Conventional Glycemic Control. Clin Ophthalmol. 2021 Jun 25;15:2767-2785. (33) Hung LT, Poon SHL, Yan WH, Lace R, Zhou L, Wong JKW, Williams RL, Shih KC, *Shum HC, *Chan YK. Sca�old-Free Strategy Using a PEG-Dextran Aqueous Two-Phase-System for Corneal Tissue Repair. ACS Biomater Sci Eng. 2022 May 9;8(5):1987-1999. (34) Li MS, Wong HL, Ip YL, Peng Z, Yiu R, Yuan H, Wai Wong JK, *Chan YK. Current and Future Perspectives on Microfluidic Tear Analytic Devices. ACS Sens. 2022 May 27;7(5):1300-1314. (35) Ma MKI, Saha C, Poon SHL, Yiu RSW, Shih KC, *Chan YK. Virtual reality and augmented reality- emerging screening and diagnostic techniques in ophthalmology: A systematic review. Surv Ophthalmol. 2022 Feb 15:S0039-6257(22)00031-5. (36) Wong HL, Hung LT, Kwok SS, Bu Y, Lin Y, Shum HC, Wang H, Lo ACY, Yam GHF, Jhanji V, *Shih KC, *Chan YK. The antiscarring role of Lycium barbarum polysaccharide on cornea epithelial-stromal injury. Exp Eye Res. 2021 Oct;211:108747. (37) Chen Y, Lam Ip Y, Zhou L, Li PY, Chan YM, Lam WC, Li KKW, Steel DH, *Chan YK. What Is the Cause of Toxicity of Silicone Oil? Materials (Basel). 2021 Dec 30;15(1):269. (38) Chan YK, Laybourne JP, Ng CO, Saha C, Yap HPY, Chandra A, Steel DH, Sandinha MT, Wong D. A study of subretinal perfluorocarbon liquid (PFCL) droplets and the physics of their retention and removal, Acta Ophthalmologica. Acta Ophthalmol. 2021 Dec;99(8):e1517-e1523. 13 HKU Eye Center Inaugural Report The University of Hong Kong
C. Research-related Awards 2021-2022 (1) Asia Pacific Academy of Ophthalmology Senior Achievement Award 2021 [Professor Christopher Leung] 2021 年亞太眼科學會高級成就獎 [Professor Christopher Leung] (2) The Japanese Ophthalmological Society International Young Investigator Award 2021 [Dr Kendrick Shih] 2021 日本眼科學會國際青年研究員獎 [Dr Kendrick Shih] Dr Shih received the award based on his 2020 publication “Lycium barbarum Polysaccharide Suppresses Expression of Fibrotic Proteins in Primary Human Corneal Fibroblasts” in Journal of Clinical Medicine, for which he served as corresponding author and principal investigator. The study was the first proof of concept that wolfberry extract; lycium barbarum polysaccharide, may serve as a potent anti-fibrotic agent a�er cornea epithelial-stromal injury. This publication has set the path for the group’s continued work in the field, with further publications in Experimental Eye Research in 2021 and 2022. Dr. Shih 因其 2020 年在 Journal of Clinical Medicine 上發表的論文“Lycium barbarum Polysaccharide Suppresses Expression of Fibrotic Proteins in Primary Human Corneal Fibroblasts”獲得該獎項，並擔任通訊作者和首席研究員。該研究首次證明了枸杞提取 物枸杞多醣，可作為角膜上皮基質損傷後的有效抗纖維化劑。該論文為研究小組的持續工作奠定了基礎，並於 2021 年和 2022 年 在Experimental Eye Research進一步發表了文章。 14 Research at HKU Ophthalmology 香港大學眼科學系——研究成果
Our research team has filed and assembled a portfolio of patented technologies 1-5* to advance the translation of novel diagnostic and therapeutic strategies in patients with blinding eye diseases. Our inventions have been licensed to multinational medical industries for clinical application. With the support from the Hong Kong Innovation and Technology Commission Technology Start-up Support Scheme for Universities, we have spun o� startup companies to translate research innovations in clinical care. Our academic sta� have been consultant to regional and global medical device and pharmaceutical companies to advise on clinical trial design and drug development. 我們的研究團隊申請及匯集了一系列專利技術 1-5*，以優化和革新對患有致盲眼疾病人的診斷和 治療策略。我們發明的技術已授權予跨國醫療公 司作臨床應用。我們得到創新科技署-大學科技初 創企業資助計劃的支持，成立初創公司，將研究 創新轉化為臨床應用。我們的學術人員更擔任區 域以至全球性的醫療設備和藥物研發公司的顧 問，就臨床試驗設計和藥物開發提供建議。 2. Research Impact 研究影響 *Patented Technologies 1. Optical Texture Analysis of the Inner Retina (US20190110681). 2. Visual Disability Detection System Using Virtual Reality (US20170273552A1). 3. Induction of chronic elevation of intraocular pressure with vinysulfonated hyaluronic acid (HA-VS) and thiolated hyaluronic acid (HA-SH) hydrogel (U.S. Patent No. 9895394B2). 4. Detection of disease-related retinal nerve fiber layer thinning (U.S. Patent No. US9117121B2). 5. Machine Learning-Based Method and System for Estimating Visual Field Sensitivities from Inner Retina Optical Texture Analysis Map (U.S. Application No. 63213469). Retinal nerve fiber layer optical texture analysis - ROTA (US20190110681) 15 HKU Eye Center Inaugural Report The University of Hong Kong
• The University of Hong Kong is one of the five Advanced Nerve Glaucoma Imaging Network (ANGI Network) Steerco member institutions, connecting Stanford University (USA), New York University (USA), University College London (UK), Moorfields Eye Hospital (UK), and Asan Medical Center (South Korea) to advance optical coherence tomography glaucoma diagnostics on an international scale. • In partnership with Arctic Vision, an ophthalmic biotech based in Shanghai China focusing on breakthrough ocular therapies, we are developing a microRNA-based ocular gene therapy for neuroprotection in patients with glaucoma – the leading cause of irreversible blindness. • Myopia is a global epidemic. In collaboration with Heidelberg Engineering, an optical coherence tomography developer in Germany, HKU - a member of the Glaucoma/Myopia OCT Phenotyping Consortium - connects 13 clinical centers in six countries (USA, Canada, Germany, Japan, South Korea, China) to unravel the structural abnormalities in myopic eyes and myopic glaucoma. • Age-related macular degeneration (AMD) is escalating with the silver tsunami. We are working with multiple pharmaceutical industries to undertake multi-center clinical trials to advance novel therapies to improve vision in patients with AMD and other retinal vascular disorders. • Supported by Santen, a Japanese pharmaceutical company, we are leading a multicenter study in Asia to determine risk factors leading to disease deterioration in glaucoma and identify therapeutic targets to avert glaucoma blindness. • 香港大學是五個高級神經青光眼成像網絡 （ANGI Network）SteerCo成員機構之一，連繫 史丹福大學（美國）、紐約大學（美國）、倫敦大 學學院（英國）、 摩菲眼科醫院（英國）和首爾峨 山病院（南韓），在全球推動以光學相干斷層掃 描技術診斷青光眼。 • 我們正與一間位於中國上海的眼科生物技術公 司- Arctic Vision合作，開發一種基於microRNA的眼部基因療法，用於保護青光眼患者的 視覺神經。 • 近視是全球流行的眼科疾病。與德國光學相干 斷層掃描開發商Heidelberg Engineering合作， 香港大學是青光眼/近視光學相干斷層掃描表型 分析聯盟的成員，連接六個國家（美國、加拿大、 德國、日本、韓國、中國）共13個診斷近視和近 視青光眼的結構異常光學相干斷層掃描臨床中 心，進行近視和青光眼研究。 • 老年黃斑部病變（AMD）正隨著高齡海嘯而升級。 我們正與多個製藥商合作，開展多中心臨床試 驗，推動新療法，以改善老年黃斑部病變和視 網膜血管疾病患者的視力。 • 在日本製藥公司Santen的支持下，我們正於亞 洲領導一項多中心研究，以確定導致青光眼疾 病惡化的風險因素，並確定治療目標以防止因 青光眼而導致失明。 3. International Collaboration and Industry Partnership for R&D in Vision Research 國際合作學術網絡 16 Research at HKU Ophthalmology 香港大學眼科學系——研究成果
17 HKU Eye Center Inaugural Report The University of Hong Kong
18 Research at HKU Ophthalmology 香港大學眼科學系——研究成果
19 HKU Eye Center Inaugural Report The University of Hong Kong
II. Technologies and Innovations at HKU Eye Centre 20
香港大學眼科中心技術與創新 ⸺ 21
1. Wide-field optical coherence tomography (OCT) – Advancing the frontier of glaucoma diagnostics 廣域光學相干斷層掃描（OCT）⸺推動青光眼診斷的前沿 「香港大學是五個高級神經青光眼成像網 絡（ANGI Network）SteerCo 成員機構之 一，連繫史丹福大學（美國）、紐約大學 （美國）、摩菲眼科醫院（英國）、倫敦大 學學院（英國）和首爾峨山病院（南韓）在 全球推動以OCT技術診斷青光眼。」 “The University of Hong Kong is one of the five Advanced Nerve Glaucoma Imaging Network (ANGI Network) SteerCo member institutions, connecting Stanford University (USA), New York University (USA), Moorfields Eye Hospital (UK), University College London (UK), and Asan Medical Center (South Korea) to advance OCT diagnostics in glaucoma care on an international scale.” 22 Technologies and Innovations at HKU Eye Center 香港大學眼科中心——技術與創新
Glaucoma is the most common cause of irreversible blindness. For many years, early diagnosis and detection of disease development and progression has been challenging even for glaucoma specialists. Recently, the advent of optical coherence tomography, a non-contact digital imaging technology, has revolutionized glaucoma diagnostics. The technology of OCT has advanced rapidly over the years and the latest generations of OCT are able to scan the retina and the optic nerve at a speed of 200 kHz (200,000 Hz) with a resolution of <2 micron, enabling wide-field imaging of the retina. The Department of Ophthalmology at HKU has been collaborating with a number of multi-national OCT developers and manufacturers to devise and pioneer innovative diagnostic technologies in the OCT systems to improve the diagnostic performance for detection of glaucoma. The University of Hong Kong is one of the five Advanced Nerve Glaucoma Imaging Network (ANGI Network) SteerCo member institutions, connecting Stanford University (USA), New York University (USA), University College London (UK), and Asan Medical Center (South Korea) to advance OCT diagnostics in glaucoma care on a global scale. 青光眼是導致永久性失明的最常見原因。多年 來，即使對青光眼專家來說，青光眼早期診斷和 進展速度的檢測也具有一定挑戰性。最近，光學 相干斷層掃描（OCT）（一種非接觸式成像技術）的 出現徹底改變了青光眼診斷。在過去幾年，OCT 技術發展迅速，最新一代的OCT能夠以200 kHz （200,000 Hz）的速度掃描視網膜和視神經，分 辨率少於2微米，可觀察視網膜的廣域成像。香 港大學眼科學系一直與多家跨國OCT開發商和 製造商合作，開拓和創新OCT系統設計和診斷技 術，以提高我們對青光眼的診斷能力及揭示青光 眼的發病機制。香港大學是五個高級神經青光 眼成像網絡（ANGI Network）SteerCo成員機構 之一，連繫史丹福大學（美國）、紐約大學（美 國）、倫敦大學學院（英國）和首爾峨山病院（南 韓），在全球推動以OCT技術診斷青光眼。 23 HKU Eye Center Inaugural Report The University of Hong Kong
「香港大學眼科學系是全球首批獲 得內置數碼手術顯微鏡技術的眼科 團隊。在這兩年以來，我們已將數 碼顯微鏡應用於白內障、視網膜和 青光眼手術和研究。」 “The Department of Ophthalmology at HKU was in the first tier to acquire the 3D digital surgical microscope during the worldwide launch......we have been applying the 3D digital microscope for cataract, retinal, and glaucoma surgeries and research for more than 2 years” 2. 3D digital surgical microscope – A paradigm shi� in ophthalmic surgery 數碼顯微鏡⸺眼科手術的模式轉變 24 Technologies and Innovations at HKU Eye Center 香港大學眼科中心——技術與創新
Ophthalmology has been a cu�ing-edge specialty, relying on high-tech instruments and pushing the forefront of microsurgery. While the surgical binocular microscope has been a long-standing piece of equipment for eye surgery, it was not until 2019 that the first 3D digital microscope – a built-in digital viewing system integrated into an ophthalmic surgical microscope – was introduced. The Department of Ophthalmology at HKU was amongst the first tier to acquire the 3D digital surgical microscope during the worldwide launch. Since the delivery in 2020, we have been applying the digital microscope for cataract, retinal, and glaucoma surgeries and research for more than 2 years. The microscope has also enhanced resident training as well as medical student teaching. The new microscope features a 3-dimensional display of the surgical field using two 4k cameras for true digital stereo vision on a 65-inch LED screen. Adopting a natural upright si�ing posture, the surgeon no longer needs to bend the neck and peek into two small eye pieces to view the surgical space. In addition, new filters, lighting features and viewing manipulations are available to see fine structures such as blood vessels, retinal layers, membranes or vitreous humor in high magnification. The viewing system also allows for much larger, detailed images with deeper field of view which can assist delicate retinal surgical procedures. With the development of the digital microscope, microsurgery has finally entered a paradigm shi�. Hong Kong will see the addition of the new digital microscope into public hospitals beginning in 2022. 眼科專科之發展一直依靠高科技儀器推動。手術 顯微鏡一直是所有眼科和眼內科手術的必備工 具。然而，直到2019年市場才推出第一台內置 數碼觀察系統的眼科手術顯微鏡。香港大學眼科 學系是全球首批獲得內置數碼手術顯微鏡技術的 眼科團隊。在這兩年以來，我們已將數碼顯微鏡 應用於白內障、視網膜和青光眼手術和研究。 該顯微鏡加強了住院醫生和醫學生培訓。 新型數碼顯微鏡具備手術視野三維顯示，並使用 兩個4K鏡頭在65英寸LED屏幕呈現真正的數碼 立體影像。外科醫生可採用自然的直立坐姿，不 再需要彎曲頸部來查看手術情況。此外，透過新 的濾光鏡、照明功能和觀察操作，可以更高倍率 查看血管、 視網膜層或玻璃體液等精細結構。系 統還容許觀察更大、更詳細的圖像，並具有更高 的視覺深度，以協助更精細的眼科外科手術程序。 隨著數碼顯微鏡的發展，香港公立醫院將於2022 年增設和應用全新的數碼顯微鏡，眼科手術治療 將進入另一個嶄新模式。 25 HKU Eye Center Inaugural Report The University of Hong Kong
3. Intense Pulsed Light Therapy (IPL) – New therapy for dry eye disease 強脈衝光治療（IPL）⸺乾眼症的全新治療選擇 「香港大學眼科學系一直致力優化針對 亞洲人群組的IPL治療，並將其應用範 圍擴展到其他形式的乾眼症。」 “The Department of Ophthalmology has been optimizing treatment se�ings of IPL therapy in Asian populations and extending its indications to other forms of dry eye disease.” 26 Technologies and Innovations at HKU Eye Center 香港大學眼科中心——技術與創新
Dry eye disease is prevalent in Hong Kong. Up to 70% of elderly patients greater than 60 years of age are su�ering from symptomatic dry eye disease, having gri�y and painful eyes, with associated blurred vision. One common cause of dry eye disease is meibomian gland dysfunction (MGD), which is a condition with insu�cient lipid secretion from meibomian gland, undermining tear film stability and producing dry eye symptoms despite normal tear secretion. Intense pulsed light (IPL) therapy, which uses light energy on the skin surface, is widely used in dermatology to treat a variety of conditions including dermal vascular lesions, such as port wine stains and hemangiomas, facial rosacea, and acne. Since April 2021, IPL is a United States Food and Drug Administration (US FDA)-approved treatment for dry eye disease due to MGD. The Department of Ophthalmology has been optimizing treatment se�ings of IPL therapy in Asian populations and extending its indications to other forms of dry eye disease, including those related to Sjogren’s syndrome and prolonged topical glaucoma medication use. 乾眼症在香港是常見的眼科疾病之一。六十歲 以上的老年患者更有高達百分之七十患有乾眼 症，眼睛會感到刺痛和視力模糊。乾眼症的其中 一個常見原因是瞼板腺功能障礙（MGD），這是 一種瞼板腺分泌脂質不足的疾病，儘管淚液分泌 正常，但會破壞淚膜穩定性並產生乾眼症症狀。 在皮膚表面使用光能量的強脈衝光（IPL）療法， 正廣泛使用於皮膚科治療各種疾病，包括皮膚血 管病變，例如鮮紅斑痣和血管瘤、面部紅斑痤瘡 和痤瘡。自2021年4月以來，美國食品和藥物管 理局（US FDA）批准利用IPL來治療由MGD引起 的乾眼症。香港大學眼科學系一直致力優化針 對亞洲人群組的IPL治療，並將其應用範圍擴展 至其他形式的乾眼症，包括與乾燥綜合徵和長期 局部青光眼藥物使用相關的乾眼症。 27 HKU Eye Center Inaugural Report The University of Hong Kong
「香港大學眼科學系多年來引入了 多種用於降低眼壓的微創青光眼手 術，我們透過申請研究基金和慈善 計劃而獲得資金，為符合條件的患 者免費提供微創青光眼治療。」 “HKU Ophthalmology has introduced a variety of MIGS procedures in Hong Kong over the recent years...... We have secured funding from research projects and charity programs to o�er MIGS procedures in eligible patients free of charge.” 4. Minimally Invasive Glaucoma Surgery (MIGS) – Balancing Safety and E�cacy for Patient Care Minimally invasive glaucoma surgery (MIGS) aims to enhance safety profile of surgery while maintaining a high e�cacy in lowering the intraocular pressure. HKU Eye Centre, as a tertiary eye centre in Hong Kong, always stands upfront to provide the safest and the most advanced technology to our patients. HKU Ophthalmology has investigated a variety of MIGS procedures including Xen, iStent, endoscopic cyclophotocoagulation, microcatheter-assisted canaloplasty, microshunt, and trabectome for intraocular pressure reduction over the recent years. We have secured funding from research projects and charity programs to o�er MIGS procedures in eligible patients free of charge. Many patients, however, require conventional glaucoma surgeries such as trabeculectomy and glaucoma drainage device to slow disease progression. We work together with our patients to select the best treatment option and strivethrive to a�ain the highest standard of care. 微創青光眼手術（MIGS）旨在提高手術的安全性， 同時能有效降低眼壓。香港大學眼科中心致力堅 持為患者提供最安全和最先進的技術。近年來， 香港大學眼科學系研究了多種用於降低眼壓的微 創青光眼手術，包括Xen、iStent、內鏡下睫狀體 光凝術、微導管輔助管成形術、微分流術和小梁 切除術。我們透過申請研究基金和慈善計劃而獲 得資金，為符合條件的患者免費提供MIGS治療。 然而，許多患者仍需要傳統的青光眼手術，例如 小梁切除術和青光眼引流裝置來減緩病情。我們 會與患者溝通，為他們選擇最合適的治療方案和 提供最好的護理。 微創青光眼手術（MIGS 平衡患者護理的安全性和）⸺有效性 28 Technologies and Innovations at HKU Eye Center 香港大學眼科中心——技術與創新
「香港大學眼科學系與世界各地之 視網膜專家合作參與香港新抗血管 內皮生長因子治療的測試和研究。」 “HKU Ophthalmology works with an international network of retinal experts, conducting landmark clinical trials in the testing of new anti-VEGF treatments.” 5. Anti-vascular endothelial growth factor (VEGF) therapy – Innovating and testing new treatments for age-related macular degeneration With the introduction of anti- vascular endothelial growth factor (VEGF), millions of patients with age-related macular degeneration have been successfully treated worldwide. HKU Ophthalmology has been closely involved in the testing of new anti-VEGF treatments in multi-center clinical trials. By bringing in longer lasting and more e�ective drugs, we minimize the treatment burden of our patients. HKU Ophthalmology works with an international network of retinal experts, conducting landmark clinical trials in the testing of ranibizumab, aflibercept, conbercept, faricimab, brolucizumab and abicipar. We continue to impact patient care by o�ering new treatment options to our patients, ensuring safety of the new treatments with evidence-based protocols. 隨著抗血管內皮生長因子（VEGF）治療的引入， 全球數百萬老年黃斑部病變患者得到治愈。香港 大學眼科學系一直參與新抗血管內皮生長因子治 療的測試和研究。通過為患者帶來更持久、更有 效的藥物，讓患者的治療負擔降至最低。香港大 學眼科學系與世界各地之視網膜專家合作，進行 了具標誌性的雷珠單抗、阿柏西普、康柏西普、 法瑞昔單抗、布西珠單抗和阿比西帕的醫學測試 和臨床試驗。我們會繼續為患者提供新的治療方 案，以循證議定為基礎確保新治療的安全性。 抗血管內皮生長因子（VEGF）療法⸺ 創新測試方案以治療老年黃斑部病變 29 HKU Eye Center Inaugural Report The University of Hong Kong
III. Community and Charity Clinical Services 30
社區及慈善臨床服務 31
1. Mr. and Mrs. Thomas Kwok Charity Cataract Surgery and Research Program 郭炳江先生夫人白內障手術服務及研究慈善計劃 Cataract surgery Donation Prolonged waiting time for cataract surgery has compromised the quality of vision and the quality of life in many cataract patients in Hong Kong, which has worsened during the COVID19 pandemic when more people became financially deprived and incapable of a�ording ophthalmology consultation and cataract surgery in the private sector. With a generous donation provided by Mr. and Mrs. Thomas Kwok, HKU ophthalmology is embarking on a cataract surgery and research program. In collaboration with Hong Kong Sheng Kung Hui Welfare Council, we will identify visually impaired individuals coming from low-income family for free professional eye exam and free cataract surgery. We aim to: (1) provide free cataract surgery to the socially disadvantaged and (2) develop new algorithms to increase the precision of refractive outcomes a�er cataract surgery using advanced imaging technologies. 長時間輪侯白內障手術影響了白內障患者的生活 質素和視力。在新冠肺炎肆虐下，香港經濟環境 大倒退，市民面對前所未有的經濟壓力，更無法 負擔在私家診所接受眼科醫療諮詢和白內障手術 的昂貴費用。香港大學眼科學系得到郭炳江先生 及夫人的慷慨捐助，開展白內障手術慈善服務及 研究計劃。我們與香港聖公會福利協會合作，甄 選來自低收入家庭的視障人士，為他們提供免費 的專業眼科檢查及白內障手術。我們的目標是︰ (1) 為弱勢社群提供免費白內障手術，以及 (2) 開發新技術以提高屈光結果的精準度，使用先 進的影像工具量度最佳的近距和遠距視力。 Professional eye exam 32 Community and Charity Clinical Services 社區及慈善臨床服務
2. Southern District Signature Project Scheme – Community Ophthalmic Examination Services 南區社區重點項目眼科檢查項目 Eye examination 50M funding support In May 2019, HKU Ophthalmology established a community eye screening programme in collaboration with the Southern District Council of Hong Kong. The project was selected as the district’s Signature Project Scheme and generously supported by the HKSAR government with the sum of HKD 50 million for start-up and operational costs. The aim of the five-year project is to provide free, comprehensive and ophthalmologist-led eye assessment and consultation service to residents of the Southern District of Hong Kong, aged 50 and above. The project has provided an important opportunity for early and accurate identification of potentially sightthreatening eye conditions, facilitating timely referral and management. 香港大學眼科學系自2019年5月聯同南區區議會 成立眼科檢查中心，為五十歲或以上的南區居民 提供免費而全面的眼科檢查服務，期望能及早察 覺隱性眼疾，令居民適時得到治療。中心同時亦 會收集眼科檢查數據作科學分析，為未來南區以 至整個香港的醫療政策提供基礎資料，並增加現 時對常見眼睛疾病的了解，長遠有助開發新的診 斷技術和治療方針。 As of 31 March 2022, we have examined a total of 11,272 Hong Kong residents. 截至2022年3月31日，我們共 檢查了11,272名香港居民。 We have identified 3411 patients with cataract; 1250 patients with glaucoma or glaucoma suspects, and 1305 patients with macular and retinal diseases. 我們確定了3411名白內障患者； 其中1250人為青光眼患者或懷疑 患有青光眼，1305人為黃斑和視 網膜疾病患者。 2,705 patients have been referred to specialist outpatient clinics for further management. 2,705 名患者被轉介至專科門診 接受進一步治療。 Most patients developing visual impairment at the early stages are not aware of the possibility of irreversible blindness years later. 大多數在早期階段出現視力障 礙的患者並沒有意識到多年後 會出現失明的可能性。 33 HKU Eye Center Inaugural Report The University of Hong Kong
Intravitreal injections of anti-VEGF to patients with age related macular degeneration (AMD) or diabetic macular edema (DME) is a demanding service in Hong Kong. HKU Ophthalmology introduced the Treat and Extend protocol in the Hospital Authority Hong Kong West Cluster (Grantham Hospital and Queen Mary Hospital) and cut down the waiting time of antiVEGF injection service. The success of the Treat and Extend protocol was acknowledged by the Hospital Authority of Hong Kong. Our retina team, led by Dr Nicholas Fung, was bestowed with the Outstanding Team awards in 2019 and in 2020. HKU Ophthalmology has helped introduce 3 anti-VEGF drugs to Hong Kong and conducted multiple clinical trials investigating their safety and e�cacy on a variety of macular diseases. 在香港，向黃斑部病變（AMD）或糖尿病黃斑水腫 （DME）患者進行玻璃體注射抗血管內皮生長因子 治療是一項艱鉅的任務。香港大學眼科學系在醫 院管理局港島西聯網（葛量洪醫院和瑪麗醫院）引 入了延伸治療方案，並縮短了玻璃體注射抗血管 內皮生長因子治療的輪候時間。有關方案成功得 到香港醫院管理局的認可。我們由馮兆基醫生帶 領的視網膜團隊分別於2019年和2020年榮獲傑 出團隊獎。此外，香港大學眼科學系已成功將3 種抗血管內皮生長因子藥物應用在香港市場，並 進行了多項臨床試驗，以研究它們對多種黃斑疾 病的安全性和有效性。 3. Anti-VEGF injection services – Meeting the unmet needs 玻璃體注射抗血管內皮生長因子治療 ⸺ 滿足未被滿足的需求 Macular degeneration Intravitreal injection 34 Community and Charity Clinical Services 社區及慈善臨床服務
The Department of Ophthalmology and the Department of Family Medicine & Primary Care at HKU introduced the universal diabetic retinopathy (DR) screening - Risk Assessment and Management Programme for Diabetes Mellitus (RAMP-DM) - in the Hospital Authority primary care clinics since 2009. Back then, the overall prevalence of DR in diabetic patients was 39% with 10% of patients requiring referral to ophthalmologists for follow-up and treatment. Our early reports showed significant risk reduction of severe DR, as well as heart, kidney, and neurological diseases among those enrolled in the program. Furthermore, patients enrolled into the screening program had lower mortality, specialist a�endance, emergency a�endance and hospitalizations compared with the non-enrolled. We estimated that a reduction of HK$56,893 in health cost for each patient enrolled in the RAMP-DM programme over a 5-year period. HKU Ophthalmology continues to play a vital role in the RAMP-DM as the HA-appointed provider for grader training and quality assurance of its DR screening service, including provision of grading arbitration service for 7,000-10,000 patients per year, and oversees the quality assurance of the DR grading service, through monitoring of graders’ performance, annual assessment, and remedial training. 自2009年起，香港大學眼科學系和家庭醫學及 基層醫療學系的研究人員在香港醫管局聯的基層 健康服務診所引入全民糖尿病視網膜病變篩查― 糖尿病風險評估和管理計劃（RAMP-DM）。當時， 我們的初步研究指出在糖尿病患者中糖尿病視網 膜病變的總體患病率為39%，其中10%的患者 需要轉介至眼科醫生進行治療 。該計劃的早期報 告顯示，參加者中患有嚴重糖尿病視網膜病變以 及心臟、腎臟和神經系統疾病的風險顯著降低 。 與非入組患者相比，接受篩查的患者死亡率、專 科就診率、急診就診率和住院率均較低 。此外， 在這5年間，我們估計每位參加糖尿病風險評估 和管理計劃的患者節省了56,893港元的醫療成 本 。香港大學眼科學系會繼續在糖尿病風險評估 和管理計劃中發揮重要作用，為醫管局指定的糖 尿病風險評估和管理計劃篩查服務提供評分員培 訓和質量保證，包括每年為7,000-10,000名患者 提供分級仲裁服務，和通過持續監測評分員的表 現、年度評估和補救培訓來確保糖尿病視網膜病 變的評分質量。 4. Screening of diabetic retinopathy – Impact on Hong Kong diabetic care 糖尿病視網膜病變篩查⸺對香港糖尿病護理的影響 Eye examination Diabetes mellitus 35 HKU Eye Center Inaugural Report The University of Hong Kong
RkJQdWJsaXNoZXIy Mzg4NDg0